Table 2 Correlation between serum exosomal circKIF20B expression and clinicopathological characteristics of NSCLC patients (n = 24/24)
Characteristic | Gefitinib sensitive | Gefitinib resistance | P-value |
|---|---|---|---|
n | 24 | 24 | Â |
Gender, n (%) | Â | Â | 0.317 |
Female | 4 (8.3%) | 8 (16.7%) | Â |
Male | 20 (41.7%) | 16 (33.3%) | Â |
Smoking status, n (%) | Â | Â | 1.000 |
No | 19 (39.6%) | 18 (37.5%) | Â |
Yes | 5 (10.4%) | 6 (12.5%) | Â |
Tumor size, n (%) | Â | Â | 0.018* |
> 3 | 10 (20.8%) | 19 (39.6%) |  |
≤ 3 | 14 (29.2%) | 5 (10.4%) |  |
Pathologic stage, n (%) | Â | Â | 0.040* |
IIIB | 18 (37.5%) | 10 (20.8%) | Â |
IV | 6 (12.5%) | 14 (29.2%) | Â |
EGFR mutation, n (%) | Â | Â | 0.724 |
19DEL | 18 (37.5%) | 20 (41.7%) | Â |
L858R | 6 (12.5%) | 4 (8.3%) | Â |
Differentiation, n (%) | Â | Â | 0.563 |
Poor | 11 (22.9%) | 14 (29.2%) | Â |
Well and moderate | 13 (27.1%) | 10 (20.8%) | Â |
Age, mean ± SD | 63.62 ± 12.31 | 63.54 ± 9.84 | 0.979 |